Association of Longitudinal Urinary Metabolic Biomarkers With ADPKD Severity and Response to Metformin in TAME-PKD Clinical Trial Participants
Open Access
- 5 December 2022
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 8 (3) , 467-477
Abstract
No abstract availableKeywords
Funding Information
- Congressionally Directed Medical Research Programs (W81XWH-15-1-0663)
- National Center for Advancing Translational Sciences
- National Institutes of Health (1UL1TR003098, UL1TR002544)
- US Department of Defense
This publication has 32 references indexed in Scilit:
- Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategyNature Medicine, 2013
- Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric StudyPLOS ONE, 2013
- Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMPNature, 2013
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Mechanisms of Glomerular Albumin Filtration and Tubular ReabsorptionInternational Journal of Nephrology, 2012
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences of the United States of America, 2011
- Proteinuric renal diseaseClinical Medicine, 2009
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976